2023 Q4 Form 10-Q Financial Statement
#000143774923013580 Filed on May 10, 2023
Income Statement
| Concept | 2023 Q4 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|
| Revenue | $13.00K | $43.00K | $64.00K |
| YoY Change | -87.74% | -95.59% | 6.67% |
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $941.0K | $1.181M | $1.190M |
| YoY Change | 1.84% | 1.29% | -0.92% |
| % of Gross Profit | |||
| Research & Development | $1.156M | $2.314M | $2.384M |
| YoY Change | -47.45% | 0.43% | 9.06% |
| % of Gross Profit | |||
| Depreciation & Amortization | $24.00K | $16.00K | $22.00K |
| YoY Change | 14.29% | 0.0% | 37.5% |
| % of Gross Profit | |||
| Operating Expenses | $2.097M | $3.495M | $3.574M |
| YoY Change | -32.87% | 0.72% | 5.52% |
| Operating Profit | -$3.452M | -$3.510M | |
| YoY Change | 38.3% | 5.5% | |
| Interest Expense | |||
| YoY Change | |||
| % of Operating Profit | |||
| Other Income/Expense, Net | $12.00K | $28.00K | $9.000K |
| YoY Change | -220.0% | -2900.0% | 350.0% |
| Pretax Income | -$2.072M | -$3.424M | -$3.501M |
| YoY Change | -31.57% | 37.12% | 5.29% |
| Income Tax | $0.00 | $0.00 | |
| % Of Pretax Income | |||
| Net Earnings | -$2.072M | -$3.424M | -$3.501M |
| YoY Change | -31.57% | 37.12% | 5.29% |
| Net Earnings / Revenue | -15938.46% | -7962.79% | -5470.31% |
| Basic Earnings Per Share | -$0.17 | -$0.17 | |
| Diluted Earnings Per Share | -$0.09 | -$0.17 | -$0.17 |
| COMMON SHARES | |||
| Basic Shares Outstanding | 21.62M | 20.22M | 20.18M |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2023 Q4 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $1.103M | $4.305M | $4.857M |
| YoY Change | -85.02% | -50.02% | -51.09% |
| Cash & Equivalents | $4.900M | $4.300M | $4.857M |
| Short-Term Investments | |||
| Other Short-Term Assets | $295.0K | $230.0K | $279.0K |
| YoY Change | -1.67% | -29.66% | -31.11% |
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | $63.00K | $115.0K | $153.0K |
| Other Receivables | $0.00 | $0.00 | $0.00 |
| Total Short-Term Assets | $1.461M | $4.650M | $5.289M |
| YoY Change | -81.42% | -49.19% | -50.39% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $94.00K | $139.0K | $158.0K |
| YoY Change | -44.71% | -31.86% | -18.97% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $171.0K | $171.0K | $172.0K |
| YoY Change | 0.0% | 0.0% | 0.0% |
| Total Long-Term Assets | $1.526M | $1.739M | $1.839M |
| YoY Change | -20.89% | -17.74% | -15.6% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $1.461M | $4.650M | $5.289M |
| Total Long-Term Assets | $1.526M | $1.739M | $1.839M |
| Total Assets | $2.987M | $6.389M | $7.128M |
| YoY Change | -69.5% | -43.29% | -44.49% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $890.0K | $686.0K | $861.0K |
| YoY Change | 30.31% | -31.33% | 12.7% |
| Accrued Expenses | $75.00K | $111.0K | $38.00K |
| YoY Change | -52.23% | 282.76% | 11.76% |
| Deferred Revenue | $0.00 | $333.0K | $340.0K |
| YoY Change | -100.0% | -64.14% | |
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $3.608M | $3.616M | $4.000M |
| YoY Change | 0.64% | 18.4% | 2.22% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | $982.0K | $1.138M | $1.228M |
| YoY Change | -25.38% | -23.0% | -21.18% |
| Total Long-Term Liabilities | $982.0K | $1.138M | $1.228M |
| YoY Change | -25.38% | -23.0% | -21.18% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $3.608M | $3.616M | $4.000M |
| Total Long-Term Liabilities | $982.0K | $1.138M | $1.228M |
| Total Liabilities | $4.590M | $4.754M | $5.228M |
| YoY Change | -6.35% | 4.9% | -4.44% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$144.1M | -$147.5M | -$144.1M |
| YoY Change | 2.49% | 9.67% | 9.17% |
| Common Stock | $24.00K | $22.00K | $20.00K |
| YoY Change | 20.0% | 22.22% | 17.65% |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | -$1.603M | $1.635M | $1.900M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $2.987M | $6.389M | $7.128M |
| YoY Change | -69.5% | -43.29% | -44.49% |
Cashflow Statement
| Concept | 2023 Q4 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$2.072M | -$3.424M | -$3.501M |
| YoY Change | -31.57% | 37.12% | 5.29% |
| Depreciation, Depletion And Amortization | $24.00K | $16.00K | $22.00K |
| YoY Change | 14.29% | 0.0% | 37.5% |
| Cash From Operating Activities | -$1.854M | -$3.151M | -$2.560M |
| YoY Change | -38.14% | 19.13% | -12.12% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $2.000K | $2.000K | $10.00K |
| YoY Change | 0.0% | -108.0% | -65.52% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | |||
| YoY Change | |||
| Cash From Investing Activities | -$2.000K | -$2.000K | -$10.00K |
| YoY Change | 0.0% | -92.0% | -65.52% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 1.116M | 2.601M | $64.00K |
| YoY Change | -69.8% | 92.1% | |
| NET CHANGE | |||
| Cash From Operating Activities | -1.854M | -3.151M | -$2.560M |
| Cash From Investing Activities | -2.000K | -2.000K | -$10.00K |
| Cash From Financing Activities | 1.116M | 2.601M | $64.00K |
| Net Change In Cash | -740.0K | -552.0K | -$2.506M |
| YoY Change | -206.32% | -58.05% | -14.82% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$1.854M | -$3.151M | -$2.560M |
| Capital Expenditures | $2.000K | $2.000K | $10.00K |
| Free Cash Flow | -$1.856M | -$3.153M | -$2.570M |
| YoY Change | -38.11% | 20.34% | -12.64% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
278000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3501000 | usd |
| CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1900000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3501000 | usd |
| CY2022Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3325000 | usd |
| CY2023Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
22000 | usd |
| CY2022Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
16000 | usd |
| CY2023Q1 | us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
79000 | usd |
| CY2022Q1 | us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
71000 | usd |
| CY2023Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
278000 | usd |
| CY2022Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
319000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-48000 | usd |
| CY2022Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
179000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-20000 | usd |
| CY2022Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-57000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease Due From Other Related Parties
IncreaseDecreaseDueFromOtherRelatedParties
|
-0 | usd |
| CY2022Q1 | us-gaap |
Increase Decrease Due From Other Related Parties
IncreaseDecreaseDueFromOtherRelatedParties
|
-0 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
345000 | usd |
| CY2022Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
257000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
226000 | usd |
| CY2022Q1 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
-201000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-1000 | usd |
| CY2022Q1 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
101000 | usd |
| CY2023Q1 | bcda |
Increase Decrease In Non Current Operating Lease Liability
IncreaseDecreaseInNonCurrentOperatingLeaseLiability
|
-76000 | usd |
| CY2022Q1 | bcda |
Increase Decrease In Non Current Operating Lease Liability
IncreaseDecreaseInNonCurrentOperatingLeaseLiability
|
-29000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-2560000 | usd |
| CY2022Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-2913000 | usd |
| CY2023Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
10000 | usd |
| CY2022Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
29000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-10000 | usd |
| CY2022Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-29000 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
244000 | usd |
| CY2022Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
0 | usd |
| CY2023Q1 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
180000 | usd |
| CY2022Q1 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
-0 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
64000 | usd |
| CY2022Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
0 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-2506000 | usd |
| CY2022Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-2942000 | usd |
| CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
7363000 | usd |
| CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
12872000 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
4857000 | usd |
| CY2022Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
9930000 | usd |
| CY2023Q1 | us-gaap |
Stock Issued1
StockIssued1
|
6000 | usd |
| CY2022Q1 | us-gaap |
Stock Issued1
StockIssued1
|
0 | usd |
| CY2023Q1 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
861000 | usd |
| CY2022Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
683000 | usd |
| CY2023Q1 | bcda |
Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
|
2472000 | usd |
| CY2022Q4 | bcda |
Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
|
2246000 | usd |
| CY2023Q1 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
340000 | usd |
| CY2022Q4 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
341000 | usd |
| CY2023Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
327000 | usd |
| CY2022Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
315000 | usd |
| CY2023Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
4000000 | usd |
| CY2022Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
3585000 | usd |
| CY2023Q1 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
1228000 | usd |
| CY2022Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
1316000 | usd |
| CY2023Q1 | us-gaap |
Liabilities
Liabilities
|
5228000 | usd |
| CY2022Q4 | us-gaap |
Liabilities
Liabilities
|
4901000 | usd |
| CY2023Q1 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
usd | |
| CY2023Q1 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
usd | |
| CY2023Q1 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2022Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2023Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
25000000 | |
| CY2022Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
25000000 | |
| CY2023Q1 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | usd |
| CY2022Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | usd |
| CY2023Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2022Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2023Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
| CY2022Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
| CY2022Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
20076773 | |
| CY2022Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
20076773 | |
| CY2023Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
20000 | usd |
| CY2022Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
20000 | usd |
| CY2023Q1 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
145985000 | usd |
| CY2022Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
145476000 | usd |
| CY2023Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-144105000 | usd |
| CY2022Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-140604000 | usd |
| CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1900000 | usd |
| CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
4892000 | usd |
| CY2023Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
7128000 | usd |
| CY2022Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
9793000 | usd |
| CY2023Q1 | us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
64000 | usd |
| CY2022Q1 | us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
60000 | usd |
| CY2023Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
2384000 | usd |
| CY2022Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
2186000 | usd |
| CY2023Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
9000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3501000 | usd |
| CY2022Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3325000 | usd |
| CY2023Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.17 | |
| CY2022Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.19 | |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
20177167 | |
| CY2022Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
17066068 | |
| CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
10375000 | usd |
| CY2023Q1 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0000925741 | |
| CY2023Q1 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2023Q1 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
| CY2023Q1 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2023 | |
| CY2023Q1 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q1 | |
| CY2022Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd |
| CY2023Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd |
| CY2022Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
319000 | usd |
| CY2022Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3325000 | usd |
| CY2022Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
7369000 | usd |
| CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
4892000 | usd |
| CY2023Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
0 | usd |
| CY2023Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 45pt;"> </td> <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><i>(b)</i></b></p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><i>Liquidity </i></b>–<b><i> Going Concern</i></b></p> </td> </tr> <tr style="vertical-align: top;"> <td style="width: 45pt;"> </td> <td style="width: 18pt;"> </td> <td style="width: auto;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;"> </p> </td> </tr> <tr style="vertical-align: top;"> <td style="width: 45pt;"> </td> <td style="width: 18pt;"> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">We have incurred net losses and negative cash flows from operations since our inception and had an accumulated deficit of approximately $144.1 million as of March 31, 2023. Management expects operating losses and negative cash flows to continue through at least the next several years. We expect to incur increasing costs as we advance our trials and development activities. Therefore, absent additional funding, management believes cash and cash equivalents of $4.9 million as of March 31, 2023 are not sufficient to fund the Company’s planned expenditures and meet its obligations beyond the third quarter of 2023. These factors raise substantial doubt about our ability to continue as a going concern beyond one year from the date these financial statements are issued. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Our ability to continue as a going concern and to continue further development of our therapeutic candidates beyond the third quarter of 2023 will require us to raise additional capital. We plan to raise additional capital, potentially including debt and equity arrangements, to finance our future operations. While management believes this plan to raise additional funds will alleviate the conditions that raise substantial doubt, these plans are not entirely within its control and cannot be assessed as being probable of occurring. If adequate funds are not available, we may be required to reduce operating expenses, delay or reduce the scope of our product development programs, obtain funds through arrangements with others that may require us to relinquish rights to certain of our technologies or products that we would otherwise seek to develop or commercialize, or cease operations.</p> </td> </tr> </tbody></table> | |
| CY2023Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-144100000 | usd |
| CY2023Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
4900000 | usd |
| CY2023Q1 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 45pt;"> </td> <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><i>(e)</i></b></p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><i>Concentration of Credit Risk</i></b></p> </td> </tr> <tr style="vertical-align: top;"> <td style="width: 45pt;"> </td> <td style="width: 18pt;"> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Financial instruments that potentially subject us to a concentration of credit risk consist of cash and cash equivalents. Our cash at times exceeds federally insured limits of $250,000 per customer. On March 31, 2023, substantially all of our cash was held by one financial institution and the amount on deposit was approximately $4.5 million in excess of FDIC insurance limits. We have not recognized any losses from credit risks on such accounts since inception.</p> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Silicon Valley Bank (SVB) was closed on March 10, 2023 by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (FDIC) as receiver. As of March 31, 2023, the Company has transferred substantially all of its cash and cash equivalents from SVB to another financial institution and does not believe it will be impacted by the closure of SVB.</p> </td> </tr> </tbody></table> | |
| CY2023Q4 | us-gaap |
Cash Uninsured Amount
CashUninsuredAmount
|
4500000 | usd |
| CY2023Q1 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
799000 | usd |
| CY2022Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
789000 | usd |
| CY2023Q1 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
641000 | usd |
| CY2022Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
619000 | usd |
| CY2023Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
158000 | usd |
| CY2022Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
170000 | usd |
| us-gaap |
Depreciation
Depreciation
|
22000 | usd | |
| us-gaap |
Depreciation
Depreciation
|
16000 | usd | |
| CY2023Q1 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
121000 | usd |
| CY2022Q1 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
121000 | usd |
| CY2023Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
118000 | usd |
| CY2022Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
97000 | usd |
| CY2023Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P3Y10M2D | |
| CY2023Q1 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
10.74 | pure |
| CY2023Q1 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
114000 | usd |
| CY2023Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
485000 | usd |
| CY2023Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
499000 | usd |
| CY2023Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
514000 | usd |
| CY2023Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
44000 | usd |
| CY2023Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
1656000 | usd |
| CY2023Q1 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
101000 | usd |
| CY2023Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
1555000 | usd |
| CY2023Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
38000 | usd |
| CY2022Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
157000 | usd |
| CY2023Q1 | bcda |
Accrued Salaries And Employee Benefits Current
AccruedSalariesAndEmployeeBenefitsCurrent
|
1100000 | usd |
| CY2022Q4 | bcda |
Accrued Salaries And Employee Benefits Current
AccruedSalariesAndEmployeeBenefitsCurrent
|
899000 | usd |
| CY2023Q1 | bcda |
Accured Clinical Trial Costs
AccuredClinicalTrialCosts
|
693000 | usd |
| CY2022Q4 | bcda |
Accured Clinical Trial Costs
AccuredClinicalTrialCosts
|
548000 | usd |
| CY2023Q1 | bcda |
Grant Liability Current
GrantLiabilityCurrent
|
518000 | usd |
| CY2022Q4 | bcda |
Grant Liability Current
GrantLiabilityCurrent
|
534000 | usd |
| CY2023Q1 | bcda |
Customer Deposit Liabilities Current
CustomerDepositLiabilitiesCurrent
|
90000 | usd |
| CY2022Q4 | bcda |
Customer Deposit Liabilities Current
CustomerDepositLiabilitiesCurrent
|
90000 | usd |
| CY2023Q1 | bcda |
Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
|
2472000 | usd |
| CY2022Q4 | bcda |
Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
|
2246000 | usd |
| CY2022Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
2424724 | |
| CY2022Q4 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
6.36 | |
| CY2023Q1 | bcda |
Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
|
0 | |
| CY2023Q1 | bcda |
Class Of Warrant Or Right Issued During Period Weighted Average Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice
|
0 | |
| CY2023Q1 | bcda |
Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
|
0 | |
| CY2023Q1 | bcda |
Class Of Warrant Or Right Exercised During Period Weighted Average Exercise Price
ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageExercisePrice
|
0 | |
| CY2023Q1 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
2424724 | |
| CY2023Q1 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
6.36 | |
| CY2023Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
278000 | usd |
| CY2022Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
319000 | usd |
| CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
2182708 | |
| CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
4.04 | |
| CY2022 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P7Y6M | |
| CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
343000 | usd |
| CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
199 | |
| CY2023Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
1.49 | |
| CY2023Q1 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
14059 | |
| CY2023Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
2.77 | |
| CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
2168450 | |
| CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
4.05 | |
| CY2023Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P7Y3M18D | |
| CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
256000 | usd |
| CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
1241371 | |
| CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
5.27 | |
| CY2023Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P6Y3M18D | |
| CY2023Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
49000 | usd |
| CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
|
4.34 | |
| CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
|
2734 | |
| CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
|
4.26 | |
| CY2023Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
4595908 | |
| CY2022Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
4046556 | |
| CY2023Q1 | us-gaap |
Loss Contingency Disclosures
LossContingencyDisclosures
|
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 36pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>(12)</b></p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Contingencies and Uncertainties</b></p> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 63pt; text-align: justify;"><i>Contingencies</i> - We may be subject to various claims, complaints, and legal actions that arise from time to time in the normal course of business. Management is not aware of any current legal or administrative proceedings that are likely to have an adverse effect on our business, financial position, results of operations, or cash flows.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 63pt;"><i>Uncertainties</i> - The results for the three months ended March 31, 2023 are not necessarily indicative of the results to be expected for the year ending December 31, 2023 or for any other interim period or for any other future year, particularly in light of COVID-19 and its impact on domestic and global economies. Governmental and business reactions to the pandemic, and resulting economic disruptions, have the potential to materially impact our business and influence our business decisions. While the impact of COVID-19 did not have a material adverse effect on our financial position or results of operations for the periods presented, our future assessment of the magnitude and duration of COVID-19 and related factors, could result in material impacts to our financial statements in future reporting periods.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> |
